# Blue Jet Healthcare (BLUEJET) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/bluejet

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹557.75
- Change: -3.23%
- As of: 2026-11-06
- 1D return: -3.23%
- 5D return: +10.54%
- 1M return: +7.56%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

BLUEJET (₹557.75, 2026-11-06) exhibits a sharp divergence between short-term momentum and long-term trend structure. Daily indicators show an established bullish trend (ADX 33.55), with price trading above all major moving averages and the Supertrend. This is corroborated by extreme volume participation on 2026-11-05 (+8.4% return, volume ratio 39.42) and a subsequent high-severity weekly downward anomaly on 2026-11-06 (-3.2% return, volume ratio 3.85). However, the monthly chart remains bearish, with price below all key averages and the Supertrend, indicating the current rally is a counter-trend move within a longer-term downtrend. The stock sits in the upper-middle of its 20-day and 252-day ranges (+67.9% and +64.0%, respectively), facing immediate resistance at ₹570.87 (pivot) and ₹572.50 (high). Risk remains elevated with annualized volatility at +50.4% and a maximum drawdown of -67.6%. A daily close above ₹572.50 would confirm further upside; a break below ₹543.70 would invalidate the short-term bullish setup.

- Trend Divergence: Daily trend is bullish (price above all MAs/Supertrend, ADX 33.55), but monthly trend remains bearish (price below all MAs/Supertrend).
- Volume & Momentum: Extreme buying volume on 2026-11-05 (+8.4%) followed by high-volume selling pressure on 2026-11-06 (-3.2%), signaling contested levels.
- Key Levels: Immediate resistance at ₹570.87 (pivot) and ₹572.50 (high); support at ₹543.70 (low). Current price ₹557.75 is near support.
- Risk Profile: High volatility (+50.4% annualized) and significant historical drawdown (-67.6% max) persist despite recent +17.3% 10-day gain.

- Bullish Engulfing Reversal
- Morning Star
- Outside Bar
- Doji
- Harami

### News Context

Blue Jet Healthcare reported unaudited standalone financial results for the half-year ended September 30, 2026, on November 5, 2026. The company posted revenue from operations of ₹6,688.57 million and a profit of ₹1,807.81 million for the six-month period. For the second quarter (Q2 FY27), revenue was ₹3,757 million with an EBITDA margin of 32% and PAT margin of 27%. Concurrently, Blue Jet completed a Qualified Institutional Placement (QIP), allotting 1,58,10,276 equity shares to Qualified Institutional Buyers at ₹506 per share, raising ₹8,000.00 million. A monitoring report by CARE Ratings Limited confirmed that ₹245.91 crore of the QIP proceeds had been utilized by quarter-end, with ₹554.08 crore remaining unutilized. Utilization included ₹215.41 crore for working capital and ₹21.10 crore for issue expenses, while no funds were deployed for equipment or civil construction during the quarter. The statutory auditor’s limited review found no material misstatements in the financial disclosures.

- Halftime Financials: Revenue from operations stood at ₹6,688.57 million and profit at ₹1,807.81 million for the six months ended September 30, 2026.
- Q2 Performance: Quarter-specific revenue was ₹3,757 million, yielding an EBITDA margin of 32% and a PAT margin of 27%.
- QIP Completion: The company raised ₹8,000.00 million via QIP at ₹506 per share, issuing 1,58,10,276 shares to eligible QIBs.
- Fund Utilization: Of the ₹800 crore QIP proceeds, ₹245.91 crore was utilized (primarily for working capital) as of September 30, 2026, with no deviation reported by the monitoring agency.

- Publication of Unaudited Standalone Financial Results of the Company for the Quarter and Half year ended September 30, 2026 under Regulation 47 of SEBI (LODR) Regulations, 2015. |SUBJECT: Copy of Newspaper Publication
- Blue Jet Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting
- Blue Jet Healthcare Limited has informed the Exchange about Presentation |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Monitoring Agency Report for the quarter ended September 30, 2026 |SUBJECT: Monitoring Agency Report
- Blue Jet Healthcare Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### What Changed

Blue Jet Healthcare reported Q2 FY27 financial results for the quarter ended September 30, 2026, on November 5–6, 2026. The company posted revenue from operations of ₹3,757 million, with an EBITDA of ₹1,188 million (32% margin) and PAT of ₹1,025 million (27% margin). Concurrently, CARE Ratings Limited submitted its Monitoring Agency Report for the quarter ended September 30, 2026, regarding the utilization of ₹800 crore QIP proceeds. The report confirmed no deviation from approved objects, noting that ₹245.91 crore had been utilized by quarter-end, while ₹554.08 crore remained unutilized. Utilization during the quarter focused on working capital (₹215.41 crore) and issue expenses (₹21.10 crore), with no funds allocated to equipment or Anakapalli facility construction. GCP proceeds were applied to capital expenditure not explicitly specified in the placement document but approved by the Managing Director and Investment and Finance Committee. Market data as of November 6, 2026, shows a share price of ₹557.75, up from ₹531.85.

- Q2 FY27 Financials: Revenue of ₹3,757 million; EBITDA margin of 32%; PAT margin of 27%.
- QIP Fund Utilization: ₹245.91 crore utilized out of ₹800 crore; ₹554.08 crore unutilized at quarter-end.
- Monitoring Update: No deviation from approved objects; GCP proceeds used for approved capital expenditure outside explicit placement document specifications.
- Price Movement: Share price rose to ₹557.75 on November 6, 2026, from ₹531.85 previously.

- [Publication of Unaudited Standalone Financial Results of the Company for the Quarter and Half year ended September 30, 2026 under Regulation 47 of SEBI (LODR) Regulations, 2015. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/BLUEJET_06112026101612_SE_Upload_Newspaper_Intimation.pdf)
- [Blue Jet Healthcare Limited has informed the Exchange about Presentation |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026160826_SE_Upload_.pdf)
- [Monitoring Agency Report for the quarter ended September 30, 2026 |SUBJECT: Monitoring Agency Report](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026162111_SE_Upload_Monitoing_Agebcy_Report.pdf)
- [Blue Jet Healthcare Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026200937_Intimation_Audio_recording_FY.pdf)

### Official Filings

Blue Jet Healthcare Limited’s Board approved unaudited standalone financial results for the half-year ended September 30, 2026, on November 5, 2026. The company reported revenue from operations of ₹6,688.57 million and a profit of ₹1,807.81 million for the six-month period. For the second quarter (Q2 FY27), revenue was ₹3,757 million, with an EBITDA margin of 32% and a PAT margin of 27%. Concurrently, the company completed a Qualified Institutional Placement (QIP), allotting 1,58,10,276 equity shares to Qualified Institutional Buyers at ₹506 per share, raising ₹8,000.00 million. A monitoring agency report confirmed that ₹245.91 crore of the QIP proceeds were utilized during the quarter, primarily for working capital, while ₹554.08 crore remained unutilized. Shareholding data as of September 30, 2026, indicates promoters hold 73.15% of the equity, with the public holding 26.85%.

- Half-year H2FY27 financials: Revenue from operations of ₹6,688.57 million and profit of ₹1,807.81 million.
- Q2 FY27 operational metrics: Revenue of ₹3,757 million, EBITDA margin of 32%, and PAT margin of 27%.
- QIP completion: Allotment of 1,58,10,276 shares at ₹506 per share, aggregating ₹8,000.00 million in fresh capital.
- Fund utilization status: ₹245.91 crore utilized against ₹800 crore raised; ₹554.08 crore remains unutilized as of quarter-end.

- [Publication of Unaudited Standalone Financial Results of the Company for the Quarter and Half year ended September 30, 2026 under Regulation 47 of SEBI (LODR) Regulations, 2015. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/BLUEJET_06112026101612_SE_Upload_Newspaper_Intimation.pdf)
- [Blue Jet Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026125116_SE_Upload_BM.pdf)
- [Blue Jet Healthcare Limited has informed the Exchange about Presentation |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026160826_SE_Upload_.pdf)
- [Monitoring Agency Report for the quarter ended September 30, 2026 |SUBJECT: Monitoring Agency Report](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026162111_SE_Upload_Monitoing_Agebcy_Report.pdf)
- [Blue Jet Healthcare Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026200937_Intimation_Audio_recording_FY.pdf)
- [Financial Results |Meeting Date: 05-Nov-2026](https://nsearchives.nseindia.com/corporate/BLUEJET_29102026131153_Prior_Intimation-_BM.pdf)
- [BLUE JET HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_21086_WebXMLFile_20261029_131747598.xml)
- [Board Meeting Intimation |Meeting Date: 05-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_21086_WebXMLFile_20261029_131747598.xml)
- [Blue Jet Healthcare Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_29102026132241_SE_Intimation___Investor_call.pdf)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 73.15 | PUBLIC_VAL: 26.85 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 08-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1734093_08102026105918_WEB.xml)

### Fundamentals

Blue Jet Healthcare’s operating trajectory shows a sharp sequential recovery in FY2026-27 after a significant annual contraction. In Q2, revenue from operations rose to ₹376 crore from ₹293 crore in Q1, while net profit jumped 31% to ₹103 crore and EPS increased to ₹5.46 per share. This contrasts with the full-year Mar 2026 data, which recorded a 28% year-on-year sales decline and a 34% drop in compounded profit growth over the trailing twelve months (TTM). The balance sheet reflects aggressive expansion: total assets grew to ₹2,584 crore by September 2026, driven by a surge in borrowings to ₹44 crore and Capital Work-in-Progress (CWIP) reaching ₹301 crore as of March 2026. While Return on Equity remains robust at 19% for the last fiscal year, the Cash Conversion Cycle lengthened to 240 days in March 2026, indicating higher working capital intensity. Promoter holding diluted to 73.15% by September 2026, while DII participation rose to 7.48%.

- Sequential Recovery: Q2 FY2026-27 revenue reached ₹376 crore (+28% sequentially) with net profit of ₹103 crore, reversing the TTM sales decline of -28%.
- Balance Sheet Expansion: Assets surged to ₹2,584 crore by Sep 2026; borrowings tripled to ₹44 crore and CWIP more than tripled to ₹301 crore between Mar 2024 and Mar 2026.
- Earnings Quality: CFO/EBITDA ratio improved sharply to 151% in Mar 2026 from 36% in Mar 2025, though the Cash Conversion Cycle extended to 240 days.
- Ownership Shift: Promoter stake decreased to 73.15% in Sep 2026, while DIIs increased their holding to 7.48%, suggesting institutional repositioning.

### Bear Case

Blue Jet Healthcare (NSE) presents a mixed technical picture as of November 6, 2026, with significant cautionary signals emerging from longer-term trends and volatility metrics. While the daily trend remains bullish with the price at ₹557.75, the monthly timeframe has flipped to bearish, indicating a potential shift in medium-term momentum. The stock is trading below its 50-day simple moving average (SMA), which slopes down sharply by -6.1% over the last five periods, contrasting with a rising 20-day SMA slope of +8.12%. This divergence suggests short-term resilience against a weakening intermediate backdrop.

Risk levels are elevated, with an annualized volatility of +50.4% and an average true range (ATR) of 4.43%, implying substantial price fluctuation. The stock is currently in a deep drawdown of -44.8% from its peak, though it has recovered slightly from the maximum drawdown of -67.6%. Recent performance shows weakness over the past three months (-5.1%) and one month (+3.6% recovery after a -3.2% drop in the prior week). Resistance is immediate at the pivot level of ₹570.87 (2.35% above), while support sits tightly at ₹557.41. Investors should monitor whether the price can sustainably hold above the 20-day EMA or if the monthly bearish signal strengthens into further downside.

- Monthly trend has turned bearish, contrasting with the daily bullish supertrend, signaling potential medium-term momentum loss.
- Stock trades below the 50-day SMA (-6.1% slope), indicating intermediate-term weakness despite short-term 20-day SMA strength (+8.12% slope).
- High volatility persists with annualized volatility at +50.4% and ATR at 4.43%; current drawdown is -44.8% from highs.
- Immediate resistance at ₹570.87 (pivot) and ₹572.50 (high); tight support at ₹557.41 requires defense to maintain daily bullish structure.

- [Publication of Unaudited Standalone Financial Results of the Company for the Quarter and Half year ended September 30, 2026 under Regulation 47 of SEBI (LODR) Regulations, 2015. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/BLUEJET_06112026101612_SE_Upload_Newspaper_Intimation.pdf)
- [Blue Jet Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026125116_SE_Upload_BM.pdf)
- [Blue Jet Healthcare Limited has informed the Exchange about Presentation |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026160826_SE_Upload_.pdf)
- [Monitoring Agency Report for the quarter ended September 30, 2026 |SUBJECT: Monitoring Agency Report](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026162111_SE_Upload_Monitoing_Agebcy_Report.pdf)
- [Blue Jet Healthcare Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026200937_Intimation_Audio_recording_FY.pdf)
- [Financial Results |Meeting Date: 05-Nov-2026](https://nsearchives.nseindia.com/corporate/BLUEJET_29102026131153_Prior_Intimation-_BM.pdf)
- [BLUE JET HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_21086_WebXMLFile_20261029_131747598.xml)
- [Board Meeting Intimation |Meeting Date: 05-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_21086_WebXMLFile_20261029_131747598.xml)
- [Blue Jet Healthcare Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_29102026132241_SE_Intimation___Investor_call.pdf)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 73.15 | PUBLIC_VAL: 26.85 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 08-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1734093_08102026105918_WEB.xml)

### FAQs

**What were Blue Jet Healthcare's financial results for the half-year ended September 30, 2026?**

For the six months ended September 30, 2026, Blue Jet Healthcare reported revenue from operations of ₹6,688.57 million and a profit for the period of ₹1,807.81 million. The Board approved these unaudited standalone results on November 5, 2026.

**How much capital did Blue Jet raise through its QIP, and how are the proceeds being utilized?**

The company allotted 1,58,10,276 equity shares to Qualified Institutional Buyers (QIBs) at ₹506 per share, raising ₹8,000.00 million. As of September 30, 2026, ₹245.91 crore was utilized (primarily for working capital), while ₹554.08 crore remained unutilized. CARE Ratings confirmed no deviation from the specified objects.

- [Publication of Unaudited Standalone Financial Results of the Company for the Quarter and Half year ended September 30, 2026 under Regulation 47 of SEBI (LODR) Regulations, 2015. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/BLUEJET_06112026101612_SE_Upload_Newspaper_Intimation.pdf)
- [Blue Jet Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026125116_SE_Upload_BM.pdf)
- [Blue Jet Healthcare Limited has informed the Exchange about Presentation |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026160826_SE_Upload_.pdf)
- [Monitoring Agency Report for the quarter ended September 30, 2026 |SUBJECT: Monitoring Agency Report](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026162111_SE_Upload_Monitoing_Agebcy_Report.pdf)
- [Blue Jet Healthcare Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026200937_Intimation_Audio_recording_FY.pdf)
- [Financial Results |Meeting Date: 05-Nov-2026](https://nsearchives.nseindia.com/corporate/BLUEJET_29102026131153_Prior_Intimation-_BM.pdf)
- [BLUE JET HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_21086_WebXMLFile_20261029_131747598.xml)
- [Board Meeting Intimation |Meeting Date: 05-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_21086_WebXMLFile_20261029_131747598.xml)
- [Blue Jet Healthcare Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/BLUEJET_29102026132241_SE_Intimation___Investor_call.pdf)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 73.15 | PUBLIC_VAL: 26.85 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 08-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1734093_08102026105918_WEB.xml)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹570.87
- Risk regime: Higher Price Risk

### Support levels
- 557.4125
- 543.7
- 540.69375

### Resistance levels
- 572.5
- 582.75
- 601.275

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -3.23% |
| return_10 | +17.29% |
| return_1m | +3.64% |
| return_1y | -0.69% |
| return_20 | +7.56% |
| return_3m | -5.13% |
| return_5 | +10.54% |
| return_6m | +13.95% |
| return_since_start | -3.41% |
| return_ytd | +5.43% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -67.61% |
| annualized_volatility | +50.36% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Blue Jet Healthcare Limited Q2 FY2026-27: Revenue climbs 28% sequentially

Blue Jet Healthcare’s revenue from operations rose 28% quarter on quarter to ₹375.7 crore in Q2 FY2026-27, while profit after tax increased 31% to ₹102.5 crore. Revenue and profit were also substantially higher year on year, but operating cash flow was negative and investing outflows were large; the quarter included an ₹800 crore fundraise and a marked increase in equity and financial assets.

## Revenue growth and operating costs

Revenue from operations increased from ₹293.1 crore in Q1 FY2026-27 to ₹375.7 crore in Q2, extending a sequential rise across the past four quarters. It was up 127% from ₹165.5 crore in Q2 FY2025-26. Total income, including ₹26.2 crore of other income, was ₹402.0 crore, a 30% increase from the prior quarter.

Expenses rose 31% quarter on quarter to ₹264.6 crore. Costs included ₹201.6 crore for materials consumed and ₹20.4 crore in employee benefits. Other expenses increased 14% to ₹43.3 crore, more slowly than total expenses.

## Profit and per-share earnings

Profit before tax increased 30% sequentially to ₹137.4 crore from ₹105.9 crore in Q1 FY2026-27. It was 100% higher than the ₹68.7 crore recorded in Q2 FY2025-26. Tax expense was ₹34.9 crore, leaving profit after tax of ₹102.5 crore, up 31% quarter on quarter and 97% year on year.

Basic and diluted earnings per share from continuing operations were ₹5.46, versus ₹4.51 in Q1 FY2026-27 and ₹3.01 in Q2 FY2025-26. Finance costs were ₹64.1 lakh, slightly below ₹66 lakh in the prior quarter. Trailing-twelve-month EPS was ₹16.00.

## Cash flow and liquidity

Operating cash flow was negative ₹25.6 crore, while investing cash flow was negative ₹711.5 crore. Free cash flow was negative ₹737.1 crore, and financing cash flow was positive ₹753.0 crore. The company reported ₹800 crore raised as of 30 September 2026.

At quarter end, cash and cash equivalents were ₹76.7 crore and other bank balances were ₹324.9 crore. Current investments stood at ₹604.6 crore. For comparison, other bank balances were ₹88.0 crore at 31 March 2026. These quarter-end balances, alongside the negative cash flows, make liquidity and the use of funds important to track.

## Balance sheet and capital base

Total assets rose to ₹2,583.9 crore at 30 September 2026 from ₹1,641.2 crore at 31 March 2026. Equity attributable to owners of the parent increased to ₹2,298.6 crore from ₹1,359.9 crore. Equity share capital was ₹37.9 crore, compared with ₹34.7 crore at 30 June 2026.

Capital work in progress increased to ₹357.9 crore from ₹301.4 crore at 31 March 2026. Property, plant and equipment was ₹325.8 crore, and noncurrent investments were ₹70.1 crore at quarter end.

## Working capital

Inventories were ₹251.3 crore and trade receivables were ₹444.7 crore at 30 September 2026, compared with ₹187.4 crore and ₹339.0 crore, respectively, at 31 March 2026. Dues to creditors other than micro and small enterprises were ₹40.0 crore, down from ₹50.7 crore at the March year end.

## Management commentary

The company said it allotted 1,58,10,276 equity shares during the quarter and reported ₹800 crore raised. It described its activities in artificial sweeteners, contrast media intermediates, pharma intermediates and APIs as a single reportable business segment. The unaudited results for the three and six months ended 30 September 2026 were reviewed by the audit committee and approved by the board on 5 November 2026, and were reviewed by the statutory auditor.

## Key Takeaway

Q2 extended Blue Jet’s strong sequential growth in revenue and earnings, with profit rising faster than sales. The ₹800 crore raise coincided with a significant expansion in equity and financial assets, while operating cash flow remained negative and investing outflows were substantial. The relationship between ongoing growth, investment spending and cash generation will be important to monitor.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q2
- As of: 2026-09-30
- Promoter holding: +73.15%
- FII holding: +0.81%
- DII holding: +7.48%
- Mutual fund holding: +4.10%
- Retail holding: +10.00%
- Promoter pledged: +0.00%

### Major reported shareholders

- Akshay Bansarilal Arora — +57.55%
- Shiven Akshay Arora — +10.04%
- Archana Akshay Arora — +5.55%
- Shamyak Investment Private Limited — +2.87%
- Icici Prudential Healthcare Fund — +2.76%

## Official filings

- 2026-11-06 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_06112026101612_SE_Upload_Newspaper_Intimation.pdf)
- 2026-11-05 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026125116_SE_Upload_BM.pdf)
- 2026-11-05 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026160826_SE_Upload_.pdf)
- 2026-11-05 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026162111_SE_Upload_Monitoing_Agebcy_Report.pdf)
- 2026-11-05 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_05112026200937_Intimation_Audio_recording_FY.pdf)
- 2026-10-29 — Board Meeting Notice: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_29102026131153_Prior_Intimation-_BM.pdf)
- 2026-10-29 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_21086_WebXMLFile_20261029_131747598.xml)
- 2026-10-29 — Board Meeting Notice: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_21086_WebXMLFile_20261029_131747598.xml)
- 2026-10-29 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_29102026132241_SE_Intimation___Investor_call.pdf)
- 2026-10-08 — Shareholding Disclosure: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1734093_08102026105918_WEB.xml)
- 2026-10-08 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_08102026112029_SE_Upload_Reg_74_5__BJHL.pdf)
- 2026-09-24 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_24092026163037_Trading_Window_Closure.pdf)
- 2026-09-24 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_21086_WebXMLFile_20260924_163203068.xml)
- 2026-09-22 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_22092026204114_FinalUploadresults.pdf)
- 2026-09-21 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_21092026131426_AGM_Proceedings.pdf)
- 2026-08-19 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_19082026104031_SE_Upload.pdf)
- 2026-08-18 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_18082026134349_SE_Intimation_Notice_of_AGM_F.pdf)
- 2026-08-18 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_21086_WebXMLFile_20260818_134937698.xml)
- 2026-08-18 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_18082026134827_SE_Intimation_BRSR_F.pdf)
- 2026-08-17 — Annual Report: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/annual_reports/AR_30401_BLUEJET_2025_2026_A_7366578_18082026134049.pdf)
- 2026-08-12 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_12082026122455_Stock_Exchange_Upload.pdf)
- 2026-08-07 — Generic Announcement: Blue Jet Healthcare Limited held an earnings call on August 3, 2026, to discuss financial results for the quarter ended June 30, 2026. The company reported revenue of INR293 crores and EBITDA of INR98 crores, with improvements driven by the PI vertical. Key strategic initiatives include progress on the Vizag project, with an investment of approximately INR1,000 crores over three years, and the Hyderabad R&D center expected to become operational in August 2026. The company also noted INR210 crores invested in the Mahad backward integration project for contrast media intermediates, with an additional INR40 crores committed. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_07082026103420_SEUploadTranscript.pdf)
- 2026-08-04 — Generic Announcement: Blue Jet Healthcare Limited published its unaudited standalone financial results for the quarter ended June 30, 2026, on August 4, 2026. The results were advertised in the Financial Express and Navshakti newspapers. The full financial results are available on the BSE website and the company's investor relations portal. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_04082026115159_Stock_Exchange_Upload_Newspaper.pdf)
- 2026-08-03 — Generic Announcement: Blue Jet Healthcare Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_21086_WebXMLFile_20260803_132821291.xml)
- 2026-08-03 — Generic Announcement: The Board of Directors of Blue Jet Healthcare Limited approved the unaudited standalone financial results for the quarter ended June 30, 2026. They also approved the re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman, and Mr. Shiven Akshay Arora as Managing Director, both for five-year terms effective April 13, 2027. M/s KKC & Associates LLP was approved for re-appointment as Statutory Auditors for a second five-year term. A record date of September 14, 2026, was set for a dividend of Rs. 1.2 per equity share, and the 58th Annual General Meeting is scheduled for September 21, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/BLUEJET_03082026124424_FinalUpload.pdf)

## News and market events

- 2026-11-07 — MONEYCONTROL: **Buy Blue Jet Healthcare; target of Rs 665: ICICI Securities** — ICICI Securities has issued a 'Buy' recommendation for Blue Jet Healthcare, setting a price target of Rs 665. The article provides this specific investment advice from the brokerage firm regarding the listed entity. — [Source](https://www.moneycontrol.com/news/business/buy-blue-jet-healthcare-target-of-rs-665-icici-securities-14074300.html)
- 2026-09-11 — Mint: **Dividend stocks alert! Last chance to qualify- Kalyan Jewellers, Aarti Industries, Blue Jet, Bajaj Healthcare, more** — Dividend stocks including Kalyan Jewellers, Aarti Industries, and 38 more, are poised to attract investor interest on Friday, September 11. These companies have set record dates for dividend payouts on September 12 and 14. — [Source](https://www.livemint.com/market/stock-market-news/dividend-stocks-alert-last-chance-to-qualify-kalyan-jewellers-aarti-industries-blue-jet-bajaj-healthcare-more-11789098026451.html)
- 2026-09-08 — MONEYCONTROL: **Axis AMC PMS fund dumps DMart on q-comm squeeze, exits REC over state discom credit risks** — Axis AMC, PMS, Alternates, Axis brokerage. portfolio management — [Source](https://www.moneycontrol.com/news/business/markets/axis-amc-pms-fund-dumps-dmart-on-q-comm-squeeze-exits-rec-over-state-discom-credit-risks-14024970.html)
- 2026-08-04 — MONEYCONTROL: **Buy Blue Jet Healthcare; target of Rs 680: ICICI Securities** — ICICI Securities, Blue Jet Healthcare, buy, Recommendations — [Source](https://www.moneycontrol.com/news/business/stocks/buy-blue-jet-healthcare-target-of-rs-680-icici-securities-13993613.html)
- 2026-08-03 — The Hindu: **Sensex today | Stock Market Live: Sensex up 600 pts, Nifty holds 24,500; IndiGo leads gainers** — Sensex, Nifty, Stock Price Live Updates: The fresh week began on a positive note for Indian stocks, thanks to softer crude oil prices and stable global markets. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-3rd-august-2026/article71298312.ece)
- 2026-08-03 — CNBC-TV18: **Blue Jet Healthcare Q1 Results: Shares fall 5% after profit, revenue decline from last year** — Blue Jet Healthcare's revenue from operations fell 17.4% year-on-year to ₹293 crore, down from ₹355 crore a year earlier. — [Source](https://www.cnbctv18.com/market/blue-jet-healthcare-q1-results-shares-fall-after-profit-revenue-decline-from-last-year-19960348.htm)
- 2026-08-03 — CNBC-TV18: **Q1 Results LIVE Updates: Blue Jet Healthcare shares fall over 5%; One Mobikwik up over 6%** — Q1 Results LIVE Updates: SBI Funds Management, Ather Energy, Inox India, IREDA, DOMS Industries, DLF, Escorts Kubota, CAMS, NOCIL, Nazara Tech, PNC Infra, Torrent Power, UPL, Restaurant Brands Asia, PNC Infra, KIMS, KEI Industries, Jindal Stainless, Ethos, GSK Pharma, Bluejet Healthcare, Kansai Nerolac, JM Financial, Kalpataru, Dhanuka Agritech, Texmaco Rail, are among the companies reporting their earnings today. Results reactions will come from stocks like ITC, Maruti Suzuki, Muthoot Finance, Dixon tech, and many others. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-maruti-sbi-mf-upl-dlf-ireda-ioc-dixon-persistent-muthoot-cams-escorts-ather-abb-divis-share-price-liveblog-19959998.htm)
- 2026-08-03 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty up over 200 points; IndiGo, Shriram Fin top gainers** — Sensex Today | Stock Market Live Updates: We are at the halfway mark of the day's trade, and the markets are trading on a strong footing, holding onto the gains. The Nifty is up over 200 points, rising above 24,600. The Nifty Bank is also higher, jumping over 530 points, rising to 57,600. ITC, Shriram Fin and IndiGo are top gainers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-fcnr-rupee-itc-maruti-autos-ioc-divis-zee-stl-banks-share-price-liveblog-19959976.htm)
- 2026-08-03 — MONEYCONTROL: **Trade Spotlight: How should you trade Hero MotoCorp, Anant Raj, Anthem Biosciences, KEI Industries, Escorts, BLS E-Services, and others on August 3?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,BLS E-Services,Hero MotoCorp,Jio Financial Services,Anant Raj,Anthem Biosciences,Blue Jet Healthcare,Shipping Corporation of India,KEI Industries,Escorts Kubota — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-hero-motocorp-anant-raj-anthem-biosciences-kei-industries-escorts-bls-e-services-and-others-on-august-3-13991407.html)

## Business profile

**Strategic vision:** Manufactures and supplies pharmaceutical and healthcare ingredients globally.

### Business segments
- **Contrast Media Intermediates:** Develops and manufactures high-purity contrast media intermediates used by pharmaceutical and diagnostic imaging companies worldwide, including intermediates for iodine-based and gadolinium-based contrast agents.
- **Artificial Sweeteners:** Manufactures Saccharin Sodium and Insoluble Saccharin for healthcare, pharmaceuticals, animal feed, food, and beverages, complying with major pharmacopoeial standards.
- **Protected Amino Acids & Derivatives and CDMO Services:** Offers protected amino acids, derivatives, and CDMO services for pharmaceutical intermediates and APIs, covering process development to commercialization for NCEs, intermediates, and APIs.

### Competitive strengths
- Specialization in niche chemical segments
- Extensive manufacturing experience in specific product lines
- Backward integration and indigenous sourcing of raw materials
- cGMP compliant facilities and robust regulatory support for CDMO services

## Related stocks

- [Caplin Point Laboratories Limited (Healthcare)](https://faxioms.com/stocks/caplipoint) — -1.64%
- [Cohance Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/cohance) — -3.56%
- [Concord Biotech Limited (Healthcare)](https://faxioms.com/stocks/concordbio) — -6.64%
- [Eris Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/eris) — +0.58%
- [Granules India Limited (Healthcare)](https://faxioms.com/stocks/granules) — +0.12%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/bluejet
Markdown representation: https://faxioms.com/stocks/bluejet?render=md